In the BioHarmony Drug Report Database

"Preview" Icon

Siltuximab

Sylvant (siltuximab) is an antibody pharmaceutical. Siltuximab was first approved as Sylvant on 2014-04-23. It is used to treat castleman disease in the USA. It has been approved in Europe to treat focal nodular hyperplasia. The pharmaceutical is active against interleukin-6.

 

Trade Name

 

Sylvant
 

Common Name

 

siltuximab
 

ChEMBL ID

 

CHEMBL1743070
 

Indication

 

castleman disease, focal nodular hyperplasia
 

Drug Class

 

Monoclonal antibodies: chimeric, tumors as target

Image (chem structure or protein)

Siltuximab structure rendering